Ascentage Pharma Group International key statistics and ratios

In fiscal 2025, Ascentage Pharma Group International had return on equity of -153.3%, a net margin of -216.5%, debt equal to 150.1% of equity and a current ratio of 1.79. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascentage Pharma Group International: financial ratios, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Gross margin	89.5%	86.2%	97.0%	91.5%
Net margin	−421.0%	−417.0%	−41.3%	−216.5%
Free-cash-flow margin	−408.8%	−347.9%	−13.8%	−209.3%
Return on equity	—	—	—	−153.3%
Current ratio	—	1.44	1.26	1.79
Debt to equity	0.0%	>999%	642.6%	150.1%
R&D as % of revenue	354.3%	318.5%	96.6%	198.1%
Capital spending as % of revenue	96.9%	20.8%	2.5%	4.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AAPG vs ADCT AAPG vs PLX AAPG vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascentage Pharma Group International's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascentage Pharma Group International.